BR112018005620A2 - método para transferência de gene estável e de nível elevado em linfócitos - Google Patents
método para transferência de gene estável e de nível elevado em linfócitosInfo
- Publication number
- BR112018005620A2 BR112018005620A2 BR112018005620A BR112018005620A BR112018005620A2 BR 112018005620 A2 BR112018005620 A2 BR 112018005620A2 BR 112018005620 A BR112018005620 A BR 112018005620A BR 112018005620 A BR112018005620 A BR 112018005620A BR 112018005620 A2 BR112018005620 A2 BR 112018005620A2
- Authority
- BR
- Brazil
- Prior art keywords
- lymphocytes
- transposase
- encoded
- receptor
- gene transfer
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 210000004698 lymphocyte Anatomy 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000008579 Transposases Human genes 0.000 abstract 4
- 108010020764 Transposases Proteins 0.000 abstract 4
- 108700019146 Transgenes Proteins 0.000 abstract 3
- 108091008915 immune receptors Proteins 0.000 abstract 2
- 102000027596 immune receptors Human genes 0.000 abstract 2
- 230000010354 integration Effects 0.000 abstract 2
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- 239000013612 plasmid Substances 0.000 abstract 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 1
- 240000007019 Oxalis corniculata Species 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 238000007796 conventional method Methods 0.000 abstract 1
- 238000004520 electroporation Methods 0.000 abstract 1
- 231100001231 less toxic Toxicity 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/50—Vectors for producing vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
Abstract
o método descrito aqui descreve uma nova tecnologia oferecendo eficiência não paralela, flexibilidade, utilidade e velocidade para integração estável de transgenes em linfócitos e outras células mamíferas. o novo método é baseado no uso de uma transposase codificada por mrna (por exemplo, sleeping beauty transposase) em combinação com um elemento transponível codificado por dna de minicírculo. o novo método permite taxas de transferência de gene maiores e é ao mesmo tempo menos tóxico do que o método convencional, que é o uso de transposase codificada por dna de plasmídeo em combinação com um elemento transponível codificado por dna de plasmídeo. as aplicações da invenção incluem, porém não estão limitadas à integração estável de um transgene codificando um receptor imune (por exemplo, um receptor de célula t ou um receptor de antígeno quimérico sintético) em linfócitos t humanos, com o receptor imune conferindo especificidade para uma molécula expressa por uma célula de tumor. o mrna de transposase e dna de minicírculo de transpóson podem ser introduzidos em linfócitos por métodos incluindo, porém não limitados à eletrotransferência tal como eletroporação e nucleofecção.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15002732 | 2015-09-22 | ||
EP16153490 | 2016-01-29 | ||
PCT/EP2016/072524 WO2017050884A1 (en) | 2015-09-22 | 2016-09-22 | A method for high level and stable gene transfer in lymphocytes |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018005620A2 true BR112018005620A2 (pt) | 2018-10-09 |
Family
ID=56979580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018005620A BR112018005620A2 (pt) | 2015-09-22 | 2016-09-22 | método para transferência de gene estável e de nível elevado em linfócitos |
Country Status (11)
Country | Link |
---|---|
US (1) | US20190169637A1 (pt) |
EP (1) | EP3352798A1 (pt) |
JP (2) | JP7142571B2 (pt) |
KR (1) | KR20180054718A (pt) |
CN (1) | CN108601849A (pt) |
AU (1) | AU2016325384B2 (pt) |
BR (1) | BR112018005620A2 (pt) |
CA (1) | CA2999608A1 (pt) |
EA (1) | EA201890772A1 (pt) |
HK (1) | HK1256068A1 (pt) |
WO (1) | WO2017050884A1 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
US20200063157A9 (en) * | 2016-02-26 | 2020-02-27 | Poseida Therapeutics, Inc. | Transposon system and methods of use |
EP3219800A1 (en) * | 2016-03-15 | 2017-09-20 | Max-Delbrück-Centrum Für Molekulare Medizin | A transposon-based transfection system for primary cells |
US11111483B2 (en) | 2016-12-16 | 2021-09-07 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems and methods |
US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
CN107236762A (zh) * | 2017-06-19 | 2017-10-10 | 河北浓孚雨生物科技有限公司 | 一种微环dna转染t细胞制备临床级car‑t细胞制剂的方法 |
US20200048716A1 (en) * | 2017-11-03 | 2020-02-13 | Twister Biotech, Inc | Using minivectors to treat ovarian cancer |
US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
CN112543808A (zh) | 2018-06-21 | 2021-03-23 | 比莫根生物科技公司 | 增强的hAT家族转座子介导的基因转移及相关组合物、系统和方法 |
EP3591060B1 (en) | 2018-07-04 | 2024-01-24 | Yeditepe Universitesi | An electroporation solution and an electroporation process performed with this solution |
US20220348682A1 (en) | 2018-08-30 | 2022-11-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
WO2020077178A1 (en) * | 2018-10-12 | 2020-04-16 | Ann & Robert H. Lurie Children's Hospital of Chicago | Plga-peg/pei nanoparticles and methods of use |
US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
US11026973B2 (en) | 2019-04-30 | 2021-06-08 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
MX2022002613A (es) | 2019-09-03 | 2022-06-02 | Myeloid Therapeutics Inc | Metodos y composiciones para la integracion del genoma. |
GB2606844A (en) | 2019-09-18 | 2022-11-23 | Intergalactic Therapeutics Inc | Synthetic DNA vectors and methods of use |
DE102020002394B4 (de) | 2020-04-21 | 2022-04-14 | Bundesrepublik Deutschland, vertr. durch das Bundesministerium der Verteidigung, vertr. durch das Bundesamt für Ausrüstung, Informationstechnik und Nutzung der Bundeswehr | Gasfiltrationsvorrichtung einer Schutzbelüftungseinrichtung |
KR102384173B1 (ko) * | 2020-05-22 | 2022-04-06 | 인천대학교 산학협력단 | 박테리아 인공 염색체 재조합 스크리닝 방법 |
KR102362878B1 (ko) | 2020-05-25 | 2022-02-11 | 인천대학교 산학협력단 | Cho 세포에 전이 유전자를 통합하기 위한 방법 |
JP2023549140A (ja) | 2020-11-04 | 2023-11-22 | マイエロイド・セラピューティクス,インコーポレーテッド | 操作されたキメラ融合タンパク質組成物およびその使用方法 |
CN114045305B (zh) * | 2021-10-15 | 2023-03-24 | 深圳市深研生物科技有限公司 | 多转座子系统 |
US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
US20230348561A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005512602A (ja) * | 2002-01-09 | 2005-05-12 | マイノス バイオシステムズ リミテッド | トランスポゾンベクターを使用するトランスジェニック生物における誘導性転位 |
SI1546322T1 (sl) * | 2002-07-24 | 2011-05-31 | Manoa Biosciences Inc | Vektorji na osnovi transpozona in metode integracije nukleinskih kislin |
US8137974B2 (en) * | 2005-05-17 | 2012-03-20 | Temasek Life Sciences Laboratory Limited | Transposition of maize AC/DS elements in vertebrates |
US20110047635A1 (en) * | 2006-08-28 | 2011-02-24 | University of Hawail | Methods and compositions for transposon-mediated transgenesis |
CN101962660B (zh) * | 2010-07-09 | 2012-12-12 | 上海海洋大学 | 一种基于Tgf2转座子的鱼类转基因方法及其载体和载体的制备方法 |
DE102011118018B4 (de) * | 2011-10-25 | 2017-10-26 | Plasmidfactory Gmbh & Co. Kg | Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen |
EP2971045B1 (en) * | 2013-03-13 | 2019-06-19 | Health Research, Inc. | Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen |
US20160145348A1 (en) * | 2013-03-14 | 2016-05-26 | Fred Hutchinson Cancer Research Center | Compositions and methods to modify cells for therapeutic objectives |
WO2015077615A1 (en) * | 2013-11-22 | 2015-05-28 | The Board Of Trustees Of The University Of Illinois | Engineered high-affinity human t cell receptors |
RU2752275C2 (ru) * | 2014-04-10 | 2021-07-26 | Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) | Способ и композиции для клеточной иммунотерапии |
-
2016
- 2016-09-22 JP JP2018534021A patent/JP7142571B2/ja active Active
- 2016-09-22 BR BR112018005620A patent/BR112018005620A2/pt active Search and Examination
- 2016-09-22 AU AU2016325384A patent/AU2016325384B2/en active Active
- 2016-09-22 EA EA201890772A patent/EA201890772A1/ru unknown
- 2016-09-22 US US15/761,783 patent/US20190169637A1/en active Pending
- 2016-09-22 WO PCT/EP2016/072524 patent/WO2017050884A1/en active Application Filing
- 2016-09-22 CA CA2999608A patent/CA2999608A1/en active Pending
- 2016-09-22 CN CN201680068108.1A patent/CN108601849A/zh active Pending
- 2016-09-22 EP EP16770015.2A patent/EP3352798A1/en active Pending
- 2016-09-22 KR KR1020187010577A patent/KR20180054718A/ko not_active Application Discontinuation
-
2018
- 2018-11-27 HK HK18115129.2A patent/HK1256068A1/zh unknown
-
2022
- 2022-04-13 JP JP2022066573A patent/JP2022097517A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EA201890772A1 (ru) | 2018-10-31 |
US20190169637A1 (en) | 2019-06-06 |
AU2016325384B2 (en) | 2021-07-22 |
KR20180054718A (ko) | 2018-05-24 |
AU2016325384A1 (en) | 2018-05-10 |
JP7142571B2 (ja) | 2022-09-27 |
CN108601849A (zh) | 2018-09-28 |
WO2017050884A1 (en) | 2017-03-30 |
JP2018532426A (ja) | 2018-11-08 |
HK1256068A1 (zh) | 2019-09-13 |
JP2022097517A (ja) | 2022-06-30 |
EP3352798A1 (en) | 2018-08-01 |
CA2999608A1 (en) | 2017-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018005620A2 (pt) | método para transferência de gene estável e de nível elevado em linfócitos | |
Hu et al. | Direct activation of human and mouse Oct4 genes using engineered TALE and Cas9 transcription factors | |
MX2019002498A (es) | Metodos y productos para la expresion de proteinas en celulas. | |
AU2018355587B2 (en) | Targeted replacement of endogenous T cell receptors | |
MX2020006065A (es) | Metodos y productos para la produccion y administracion de acido nucleico. | |
MX2019003674A (es) | Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas. | |
MX2021000211A (es) | Metodos y productos para transfeccion de celulas. | |
BR112016025519A2 (pt) | engenharia genética in vivo com vetores de adenovírus | |
BR112017013573A2 (pt) | rna de cadeia dupla, sequência de dna, cassete de expressão, vetor de terapia de gene, e, célula hospedeira. | |
EP4321623A3 (en) | Methods and compositions for genome editing in non-dividing cells | |
BR112018011193A2 (pt) | métodos escalonáveis para produzir vetor viral adeno-associado (aav) recombinante em sistema de cultura celular em suspensão isento de soro adequado para uso clínico | |
MX2016002306A (es) | Promotor u6 de polimerasa iii de soja y metodos de uso. | |
ES2690386T3 (es) | Composición para escindir un ADN diana que comprende un ARN guía específico para el ADN diana y el ácido nucleico que codifica la proteína Cas o la propia proteína Cas, y sus usos | |
EA201891681A1 (ru) | Новая иммуностимулирующая векторная система | |
MX2013003681A (es) | Ácidos nucleicos manipulados y métodos de uso de los mismos. | |
Wu et al. | MicroRNA‐16 targets zyxin and promotes cell motility in human laryngeal carcinoma cell line HEp‐2 | |
AR072531A1 (es) | SENAL DE POLIADENILACIoN | |
BR112018016443A2 (pt) | sistema de transposon replicativo | |
MX348776B (es) | Produccion personalizada de productos biologicos y metodo para reprogramar celulas somaticas. | |
WO2016007570A3 (en) | Engineered invariant natural killer t (inkt) cells and methods of making and using thereof | |
IN2013MU02316A (pt) | ||
MX2021004169A (es) | Composiciones y metodos para la transfeccion de celulas. | |
MX2017011915A (es) | Sistema para la expresion genica estable. | |
PH12017501859A1 (en) | Plant promoter for transgene expression | |
MX2017004686A (es) | Promotor recombinante con aumento de la expresion especifica de fibra. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |